Identify, characterize and attempt to develop as potential therapeutics human monoclonal antibodies (hmAbs) and engineered human antibody domains against several microbes which are on NIAID?s list of category A or C pathogens.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2011
Total Cost
$133,000
Indirect Cost
City
State
Country
Zip Code